Clinical Trial Search

Primary: CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk — 9.6; 13.5 proportion of participants — p=0.3117

Primary: Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug. — 1; 1; 0; 2 Participants

Primary: Number of Participants With Successful ERCP Procedure — 529 Participants

Primary: Score on Adult ADHD Investigator Symptom Rating Scale (AISRS) — 35 score on a scale

Primary: Acceptability of Movement-Oriented Behavioral Activation (MOBA) — 4.7 score on a scale — p=<0.001

Primary: Percentage of Response at Week 4 of Treatment — 61.2 percentage of participants

Primary: Number of Participants Discontinuing Study Treatment Due to TEAEs — 1; 3; 4 Participants

Primary: Overall Hematologic Response Rate by 6 Months — 46.3 Percentage of participants

Primary: Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone — 61.9; 63.9 ng*h/mL/mg

Primary: Estimated Body Fat % for Children Aged 10-17 Years Old — 18.4; 18.8 Percent body fat — p=0.87

Primary: Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort — -1.718; -0.628 Score on a scale — p== 0.0063

Primary: Weekly Moderate-Vigorous Physical Activity Minutes, Accelerometry — -21.4286; -53.9600; 19.6000; -38.6800 Minutes

Primary: HIV Stigma (Child Reports) — 75.07; 73.0; 75.29 score on a scale

Primary: Change in Leucocyte LC3 Score — 0.1; -1.8 Fold Change (Arbitrary Units)

Primary: Primary Efficacy Endpoint: Change From Baseline in Visual Analog Scale (VAS) for Pain at 90 Days — 32.8; 34.1; -35.1; -34.2 score on a scale